2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2614

Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus
Abstract Number: 1296

Hydroxychloroquine Level Decreases throughout Pregnancy: Implications for Maternal and Neonatal Outcomes
Abstract Number: 1601

Hydroxychloroquine Non-Adherence Is Associated with Higher Sledai Scores in a Predominantly Hispanic Population
Abstract Number: 2596

Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
Abstract Number: 2109

Hyperferritinemic Syndrome in a General Hospital
Abstract Number: 2334

Hypermethylation of NLRP3 Promoter Region Could be Responsible for Decreased Gene Expression, Inflammasome Malfunction and Gut Dysbiosis in Juvenile Spondyloarthritis Patients
Abstract Number: 2078

Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data
Abstract Number: 1157

Hypocomplementemia Is Closely Related to IgG Subclasses Other Than IgG4 in IgG4-Related Disease
Abstract Number: 556

Identification and Validation of S100 Salivary Proteins As Putative Biomarkers for Different Subsets of Primary Sjögren’s Syndrome Patients
Abstract Number: 180

Identification of a Functional Susceptible Variant in Distal Enhancer of Mir-146a By CRISPR-Cas9
Abstract Number: 1668

Identification of a Serum Measure of Lupus Nephritis Activity That Detects Molecular Pathways and Mechanisms Implicated in Renal Damage
Abstract Number: 1722

Identification of a Sub-Population of Autoantibodies Targeting BICD2 Cross-Reacting with CENP-a Derived Peptides in Patients with Systemic Sclerosis
Abstract Number: 758

Identification of Biomarkers Predictive of Pulmonary Arterial Hypertension in Systemic Sclerosis
Abstract Number: 1010

Identification of Circulating Biomarkers of Disease Activity and Organ Involvement in ANCA-Associated Vasculitis By Targeted Proteomics
Abstract Number: 2602

Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].